Table 2.
Unadjusted and adjusted prevalence ratios of factors associated with screening for cervical dysplasia in HIV-infected women in care in the Harris Health System, 2007.
| Characteristic | Screened No. (%) (n = 258)* |
Not screened No. (%) (n = 240)* |
Unadjusted Prevalence Ratio (95% CI) |
Adjusted Prevalence Ratio† (95% CI) |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Age (years) | ||||
| <30 | 28 (11) | 20 (8) | REF | REF |
| 30–50 | 157 (61) | 151 (63) | 0.87 (0.67–1.14) | 0.84 (0.66–1.09) |
| 50–64 | 70 (27) | 58 (24) | 0.94 (0.70–1.25) | 0.86 (0.65–1.13) |
| ≥65 | 3 (1) | 11 (5) | 0.37 (0.13–1.03) | 0.31 (0.11–0.87) |
| Race/ethnicity | ||||
| Black | 181 (70) | 183 (76) | REF | REF |
| White | 17 (7) | 17 (7) | 1.01 (0.71–1.43) | 0.98 (0.70–1.38) |
| Hispanic | 58 (22) | 37 (15) | 1.23 (1.01–1.49) | 1.27 (1.05–1.52) |
| Other | 2 (1) | 3 (1) | 0.80 (0.27–2.37) | 0.79 (0.27–2.33) |
| Characteristics of care delivery | ||||
| Clinic setting | ||||
| Specialty care | 205 (51) | 196 (49) | REF | REF |
| Family practice | 53 (55) | 44 (45) | 1.07 (0.87–1.31) | 0.96 (0.78–1.18) |
| Number of primary care visits in 2007 | ||||
| <4 | 131 (51) | 143 (60) | REF | REF |
| ≥4 | 127 (49) | 97 (40) | 1.19 (1.00–1.40) | 1.21 (1.02–1.44) |
| Risk behaviors | ||||
| HIV risk factors | ||||
| Heterosexual contact | 228 (88) | 195 (81) | REF | |
| IVDU | 20 (8) | 29 (13) | 0.76 (0.53–1.07) | |
| Other | 4 (2) | 9 (4) | 0.57 (0.25–1.30) | |
| Unknown | 6 (2) | 7 (3) | 0.86 (0.47–1.55) | |
| Current tobacco use | 65 (25) | 65 (27) | 0.95 (0.78–1.16) | |
| Current alcohol abuse | 22 (9) | 19 (8) | 1.04 (0.77–1.40) | |
| Characteristics of HIV disease | ||||
| Years since HIV diagnosis | ||||
| ≤1 | 41 (18) | 30 (17) | REF | |
| 2–10 | 130 (58) | 103 (57) | 0.97 (0.77–1.22) | |
| >10 | 53 (24) | 48 (27) | 0.91 (0.69–1.19) | |
| Taking HAART | 205 (80) | 182 (76) | 1.14 (0.91–1.43) | |
| Diagnosed with AIDS | 133 (52) | 125 (53) | 0.99 (0.84–1.17) | |
| Nadir CD4 count (cells/mm3) | ||||
| CD4 ≥350 | 58 (22) | 63 (26) | REF | |
| CD4 200–349 | 75 (29) | 59 (25) | 1.17 (0.92–1.48) | |
| CD4 <200 | 125 (48) | 118 (49) | 1.07 (0.86–1.34) | |
| Last CD4 count in 2007 (cells/mm3) | ||||
| CD4 ≥350 | 169 (66) | 142 (60) | REF | REF |
| CD4 200–349 | 48 (19) | 36 (15) | 1.05 (0.85–1.30) | 1.04 (0.85–1.27) |
| CD4 <200 | 40 (16) | 59 (25) | 0.74 (0.57–0.96) | 0.77 (0.59–1.00) |
| Last HIV RNA in 2007 (copies per mL) | ||||
| <=400 | 129 (54) | 102 (47) | REF | |
| 401–20,000 | 55 (23) | 44 (20) | 0.99 (0.81–1.23) | |
| 20,000–100,000 | 25 (11) | 33 (15) | 0.77 (0.56–1.06) | |
| 100,000–500,000 | 17 (7) | 19 (9) | 0.85 (0.59–1.22) | |
| >500,000 | 12 (5) | 21 (10) | 0.65 (0.41–1.04) | |
| Gynecologic History | ||||
| No history of abnormal cervical screening | 139 (52) | 126 (48) | REF | REF |
| History of abnormal screening for cervical dysplasia | 111 (56) | 86 (44) | 1.07 (0.91–1.27) | 1.07 (0.91–1.26) |
| Previous hysterectomy | 49 (19) | 36 (15) | 1.14 (0.93–1.40) | |
*
Totals may not add up to 498 because of missing values. Totals may not equal 100% because of rounding.
†
Factors for which estimates are listed were included in the multivariable model.
CI, confidence interval
IVDU, intravenous drug use
HAART, highly active antiretroviral therapy